Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium - GlobeNewswire
5/11/2022 12:00:00 AM2 years 11 months ago
by Gain Therapeutics, Inc.
by Gain Therapeutics, Inc.
Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in......
BETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a biotechnology company transforming drug discovery with its proprietary computational d… [+4562 chars]
full article...